바이오의약품 CDMO 시장 : 바이오의약품 제품 유형별, 제조 기술별, 서비스 유형별, 사업 규모별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2025-2032년)

Biologics CDMO Market size was valued at US$21,975.98 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.

The Biologics CDMO (Contract Development and Manufacturing Organization) Market refers to specialized service providers that assist biopharmaceutical companies in the development, manufacturing, and commercialization of biologic drugs. These organizations offer end-to-end solutions, including cell line development, process development, analytical testing, and large-scale manufacturing. Biologics CDMOs leverage advanced bioprocessing technologies, automation, and quality management systems to ensure regulatory compliance, product consistency, and efficiency. They help accelerate time-to-market, reduce operational complexity, and optimize production costs for pharmaceutical developers. By providing scalable and flexible biologics manufacturing solutions, CDMOs support the growth of innovative therapies, enabling broader access to safe and effective biologic treatments.

Biologics CDMO Market- Market Dynamics

Increasing Demand for Biologics

Increasing demand for biologics refers to the growing need for innovative, complex, and high-value biologic therapies across therapeutic areas, which drives biopharmaceutical companies to outsource development and manufacturing to Contract Development and Manufacturing Organizations (CDMOs). This trend enables CDMOs to expand production capacity, streamline operations, and offer end-to-end solutions that meet rising market demand. In the Biologics CDMO context, this driver supports accelerated process development, scalable manufacturing, and high-quality regulatory-compliant production. Consequently, CDMOs are able to reduce time-to-market, improve product consistency, and optimize resource utilization. Increasing demand also drives investment in advanced bioprocessing technologies, automation, and analytical capabilities, allowing CDMOs to manage larger production volumes and more complex biologics efficiently. For instance, in September 2025, the Indian pharmaceutical and biotech sector was valued at approximately Rs. 4,71,075 crore (US$ 55 billion) in FY25, and the broader industry is forecast to reach Rs. 1,13,450 crore (US$ 130 billion) by 2030, reflecting strong market growth and global competitiveness. Over the past decade, the Indian biotech industry, encompassing biologics and biosimilars, expanded from Rs. 85,650 crore (US$ 10 billion) in 2015 to Rs. 869,348 crore (US$ 101.5 billion) in 2024, driven by increasing government support, exports, and a skilled workforce. These developments illustrate the nation's strengthening position in the biologics and biosimilars space, supported by favorable policies and advancing manufacturing capabilities.

Biologics CDMO Market- Segmentation Analysis:

The Global Biologics CDMO Market is segmented on the basis of Biologics Type, Production Technology, Service Type, Scale of Operation, End User, and Region.

The market is divided into several categories based on biologic type: monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell therapies. The Monoclonal Antibodies segment accounts for a significant portion of the market due to its wide therapeutic applications and high demand across oncology, autoimmune, and infectious disease treatments. High demand for monoclonal antibodies refers to the increasing need for targeted and effective biologic therapies that address complex diseases. In Biologics CDMOs, addressing this demand is achieved through optimized process development, high-capacity production, and stringent quality control, enabling timely availability of monoclonal antibodies and ensuring patients have access to critical biologic therapies efficiently. For instance, in 2024, according to the US Government, monoclonal antibodies (mAbs) have become one of the fastest-growing classes of therapeutic agents globally, with the global mAb market valued at approximately USD 205 billion in 2023 and projected to reach over USD 300 billion by 2030, reflecting widespread clinical adoption across oncology, autoimmune diseases, and infectious diseases. By 2023, over 120 monoclonal antibody therapies were approved, with expansion into low- and middle-income countries boosting global access. These trends highlight that growing demand for targeted biologic therapies is driving increased investment in manufacturing capacity, regulatory support, and global collaboration to enhance accessibility and health outcomes.

The market is divided into three categories based on production technology: mammalian cell culture, microbial fermentation, and plant-based expression systems. The Mammalian Cell Culture segment accounts for a significant portion of the market due to its ability to produce complex and high-quality biologics with proper post-translational modifications. High efficiency and versatility in production refer to the capability of a technology to reliably generate large quantities of biologics while maintaining structural and functional integrity. In mammalian cell culture-based production, this efficiency and versatility allow biologics CDMOs to meet growing global demand, optimize yields, and produce complex molecules such as monoclonal antibodies and recombinant proteins with high precision and reproducibility. For instance, in 2024, according to the GFI Europe Organization report, the total plant-based food retail market in Germany, Europe's largest plant-based market, was valued at approximately €1.68 billion, marking a 1.5% increase over 2023 and a 6.8% rise compared with 2022. Additionally, unit sales reached 971 million in 2024, up 6.1% from 2023 and 11.9% relative, while sales volume climbed to 512 million kg, an increase of 7.1% versus 2023 and 13.5% versus 2022, demonstrating a continued rise in underlying demand for plant-based foods in the German retail sector. These figures highlight growing consumer engagement with plant-based options across meat, milk and drinks, yogurt, and cream categories, reflecting expanding market adoption driven by affordability and changing dietary preferences.

Biologics CDMO Market- Geographical Insights

The Biologics CDMO Market exhibits clear regional variation, shaped by differences in biopharmaceutical manufacturing capacity, regulatory frameworks, and technology adoption. North America shows steady adoption, supported by well-established biologics manufacturing infrastructure, robust R&D investment, and high demand for contract development and manufacturing services, particularly in the U.S. and Canada. Europe demonstrates consistent growth, driven by increasing investment in biologics production, supportive regulatory policies, and adoption of advanced manufacturing technologies. Asia Pacific is expanding rapidly, fueled by growing biopharmaceutical production, rising healthcare expenditure, large patient populations, and government initiatives promoting biologics development in countries such as China, India, Japan, and South Korea. In contrast, Latin America, the Middle East, and Africa are gradually strengthening their market presence, supported by improving biomanufacturing capabilities, regulatory modernization, and growing outsourcing of biologics development and production services.

United States Biologics CDMO Market - Country Insights

The United States Biologics CDMO market is experiencing steady growth, driven by a robust biopharmaceutical ecosystem and increasing outsourcing of biologics development and manufacturing. Biopharmaceutical companies are increasingly partnering with CDMOs to accelerate drug development timelines, enhance manufacturing capacity, and ensure regulatory compliance. Strong participation from leading contract development and manufacturing organizations, along with supportive policies that promote biopharmaceutical innovation and production, continues to encourage market expansion. Additionally, growing emphasis on cost-effective scalability and high-quality biologics production is further accelerating adoption across therapeutic and commercial development pipelines. For instance, in January 2024, according to the DCAT organization , the overall CDMO market is expected to grow at an annualized rate of 7.29% through 2028, with the biologics CDMO sector projected to expand from $15.1 billion in 2023 to $27.0 billion by the end of 2028 at a 12.3% CAGR, driven by expanding biotech pipelines and growing demand for complex biologics and cell- and gene-therapy services, underscoring how sustained investment and outsourcing trends are shaping the bio/pharma outsourcing landscape.

Biologics CDMO Market- Competitive Landscape:

The Biologics CDMO market is moderately concentrated, with several leading contract development and manufacturing organizations driving competition. Key players include 3P Biopharmaceuticals S.L.U., AGC Biologics, Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd., Evonik Industries AG, Rentschler Biopharma SE, Lonza, Samsung Biologics, WuXi AppTec, Catalent, Fujifilm Diosynth Biotechnologies, Recipharm, KBI Biopharma, Avid Bioservices, AbbVie Inc., Bioreliance, Thermo Fisher Scientific Inc., and Eurofins Scientific. These companies compete by providing comprehensive biologics development and manufacturing services, including cell line development, process development, clinical and commercial manufacturing, and quality control. For example, in 2024, Lonza expanded its biologics manufacturing capabilities by integrating continuous bioprocessing technologies, enabling higher production efficiency and reduced timelines for complex therapies. The market is driven by increasing demand for innovative biologic therapies, including monoclonal antibodies, recombinant proteins, and gene and cell therapies. Additionally, CDMOs are broadening their service offerings to include advanced analytical testing, regulatory support, and scalable manufacturing solutions to meet the evolving needs of biopharmaceutical companies and accelerate global access to high-quality therapies.

Recent Developments:

In July 2024, Bora Pharmaceuticals Co. Ltd announced a strategic collaboration with a leading biopharmaceutical innovator to expand its biologics CDMO capabilities and accelerate process development for complex biologic therapies. This initiative demonstrates Bora Pharmaceuticals' commitment to leveraging cutting-edge technologies to enhance manufacturing efficiency and support faster drug development timelines, potentially setting a new benchmark in the contract development and manufacturing space. The partnership is set to utilize advanced bioprocessing platforms and integrated analytics, positioning Bora Pharmaceuticals as a leader in high-performance biologics solutions.

In January 2025, Evonik Industries AG unveiled a major expansion of its biologics CDMO services through a collaboration with global biopharma partners to implement next-generation cell culture and purification technologies. This effort highlights Evonik's focus on deploying innovative manufacturing solutions to improve product quality, reduce production timelines, and meet growing demand for complex biologic therapies. The initiative reinforces Evonik's role as a key provider of advanced biologics manufacturing services and strengthens its competitive position in the evolving CDMO market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• AbbVie Inc.
• AGC Biologics
• Avid Bioservices
• Binex Co. Ltd.
• Bioreliance
• Bora Pharmaceuticals Co. Ltd.
• Catalent
• Eurofins Scientific
• Evonik Industries AG
• Fujifilm Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Recipharm
• Rentschler Biopharma SE
• Samsung Biologics
• Thermo Fisher Scientific Inc.
• WuXi AppTec
• 3P Biopharmaceuticals S.L.U.
• Others

GLOBALBIOLOGICS CDMO MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

• Cell and Gene Therapies
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines

GLOBAL BIOLOGICS CDMO MARKET, BY PRODUCTION TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

• Plant-based Expression Systems
• Mammalian Cell Culture
• Microbial Fermentation

GLOBAL BIOLOGICS CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

• Analytical Development
• Clinical Manufacturing
• Commercial Manufacturing
• Process Development
• Quality Control Testing

GLOBAL BIOLOGICS CDMO MARKET, BY SCALE OF OPERATION- MARKET ANALYSIS, 2019 - 2032

• Large Scale
• Medium Scale
• Small Scale

GLOBAL BIOLOGICS CDMO MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

• Academic Institutions
• Pharmaceutical Companies
• Biotechnology Companies

GLOBAL BIOLOGICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Biologics CDMO Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Biologics CDMO Market Snippet by Biologics Type
  • 2.1.2. Biologics CDMO Market Snippet by Production Technology
  • 2.1.3. Biologics CDMO Market Snippet by Service Type
  • 2.1.4. Biologics CDMO Market Snippet by Scale of Operation
  • 2.1.5. Biologics CDMO Market Snippet by End User
  • 2.1.6. Biologics CDMO Market Snippet by Country
  • 2.1.7. Biologics CDMO Market Snippet by Region
• 2.2. Competitive Insights

3. Biologics CDMO Key Market Trends

• 3.1. Biologics CDMO Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Biologics CDMO Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Biologics CDMO Market Opportunities
• 3.4. Biologics CDMO Market Future Trends

4. Biologics CDMO Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Biologics CDMO Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Biologics CDMO Market Landscape

• 6.1. Biologics CDMO Market Share Analysis, 2024
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Biologics CDMO Market - By Biologics Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Biologics Type, 2024&2032 (%)
  • 7.1.2. Cell and Gene Therapies
  • 7.1.3. Monoclonal Antibodies
  • 7.1.4. Recombinant Proteins
  • 7.1.5. Vaccines

8. Biologics CDMO Market - By Production Technology

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Production Technology, 2024&2032 (%)
  • 8.1.2. Plant-based Expression Systems
  • 8.1.3. Mammalian Cell Culture
  • 8.1.4. Microbial Fermentation

9. Biologics CDMO Market - By Service Type

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Service Type, 2024&2032 (%)
  • 9.1.2. Analytical Development
  • 9.1.3. Clinical Manufacturing
  • 9.1.4. Commercial Manufacturing
  • 9.1.5. Process Development
  • 9.1.6. Quality Control Testing

10. Biologics CDMO Market - By Scale of Operation

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By Scale of Operation, 2024&2032 (%)
  • 10.1.2. Large Scale
  • 10.1.3. Medium Scale
  • 10.1.4. Small Scale

11. Biologics CDMO Market - By End User

• 11.1. Overview
  • 11.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
  • 11.1.2. Academic Institutions
  • 11.1.3. Pharmaceutical Companies
  • 11.1.4. Biotechnology Companies

12. Biologics CDMO Market- By Geography

• 12.1. Introduction
  • 12.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
• 12.2. North America
  • 12.2.1. Overview
  • 12.2.2. Biologics CDMO Key Manufacturers in North America
  • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.2.4. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  • 12.2.5. North America Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
  • 12.2.6. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 12.2.7. North America Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
  • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.2.9. U.S.
    • 12.2.9.1. Overview
    • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.2.9.3. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.2.9.4. U.S. Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.2.9.5. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.2.9.6. U.S. Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.2.10. Canada
    • 12.2.10.1. Overview
    • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.2.10.3. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.2.10.4. Canada Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.2.10.5. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.2.10.6. Canada Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.3. Europe
  • 12.3.1. Overview
  • 12.3.2. Biologics CDMO Key Manufacturers in Europe
  • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.3.4. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  • 12.3.5. Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
  • 12.3.6. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 12.3.7. Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
  • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.9. Germany
    • 12.3.9.1. Overview
    • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.9.3. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.9.4. Germany Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.9.5. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.9.6. Germany Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.10. UK
    • 12.3.10.1. Overview
    • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.10.3. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.10.4. UK Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.10.5. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.10.6. UK Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.11. France
    • 12.3.11.1. Overview
    • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.11.3. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.11.4. France Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.11.5. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.11.6. France Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.12. Italy
    • 12.3.12.1. Overview
    • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.12.3. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.12.4. Italy Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.12.5. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.12.6. Italy Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.13. Spain
    • 12.3.13.1. Overview
    • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.13.3. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.13.4. Spain Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.13.5. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.13.6. Spain Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.14. The Netherlands
    • 12.3.14.1. Overview
    • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.14.3. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.14.4. The Netherlands Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.14.5. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.14.6. The Netherlands Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.15. Sweden
    • 12.3.15.1. Overview
    • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.15.3. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.15.4. Sweden Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.15.5. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.15.6. Sweden Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.16. Russia
    • 12.3.16.1. Overview
    • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.16.3. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.16.4. Russia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.16.5. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.16.6. Russia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.17. Poland
    • 12.3.17.1. Overview
    • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.17.3. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.17.4. Poland Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.17.5. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.17.6. Poland Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.18. Rest of Europe
    • 12.3.18.1. Overview
    • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.4. Asia Pacific (APAC)
  • 12.4.1. Overview
  • 12.4.2. Biologics CDMO Key Manufacturers in Asia Pacific
  • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.4.4. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  • 12.4.5. APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
  • 12.4.6. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 12.4.7. APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
  • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.9. China
    • 12.4.9.1. Overview
    • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.9.3. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.9.4. China Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.9.5. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.9.6. China Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.10. India
    • 12.4.10.1. Overview
    • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.10.3. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.10.4. India Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.10.5. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.10.6. India Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.11. Japan
    • 12.4.11.1. Overview
    • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.11.3. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.11.4. Japan Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.11.5. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.11.6. Japan Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.12. South Korea
    • 12.4.12.1. Overview
    • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.12.3. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.12.4. South Korea Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.12.5. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.12.6. South Korea Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.13. Australia
    • 12.4.13.1. Overview
    • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.13.3. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.13.4. Australia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.13.5. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.13.6. Australia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.14. Indonesia
    • 12.4.14.1. Overview
    • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.14.3. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.14.4. Indonesia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.14.5. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.14.6. Indonesia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.15. Thailand
    • 12.4.15.1. Overview
    • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.15.3. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.15.4. Thailand Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.15.5. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.15.6. Thailand Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.16. Philippines
    • 12.4.16.1. Overview
    • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.16.3. PhilippinesMarket Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.16.4. Philippines Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.16.5. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.16.6. Philippines Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.17. Rest of APAC
    • 12.4.17.1. Overview
    • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.17.3. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.17.4. Rest of APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.17.5. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.17.6. Rest of APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.5. Latin America (LATAM)
  • 12.5.1. Overview
  • 12.5.2. Biologics CDMO Key Manufacturers in Latin America
  • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.5.4. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  • 12.5.5. LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
  • 12.5.6. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 12.5.7. LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
  • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.9. Brazil
    • 12.5.9.1. Overview
    • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.9.3. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.5.9.4. Brazil Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.5.9.5. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.5.9.6. Brazil Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.10. Mexico
    • 12.5.10.1. Overview
    • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.10.3. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.5.10.4. Mexico Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.5.10.5. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.5.10.6. Mexico Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.11. Argentina
    • 12.5.11.1. Overview
    • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.11.3. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.5.11.4. Argentina Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.5.11.5. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.5.11.6. Argentina Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.12. Colombia
    • 12.5.12.1. Overview
    • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.12.3. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.5.12.4. Colombia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.5.12.5. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.5.12.6. Colombia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.13. Rest of LATAM
    • 12.5.13.1. Overview
    • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.6. Middle East and Africa
  • 12.6.1. Overview
  • 12.6.2. Biologics CDMO Key Manufacturers in Middle East and Africa
  • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.6.4. Middle East and Africa Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  • 12.6.5. Middle East and Africa Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
  • 12.6.6. Middle East and Africa Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 12.6.7. Middle East and Africa Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
  • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.9. Saudi Arabia
    • 12.6.9.1. Overview
    • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.10. United Arab Emirates
    • 12.6.10.1. Overview
    • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.11. Israel
    • 12.6.11.1. Overview
    • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.11.3. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.11.4. Israel Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.11.5. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.11.6. Israel Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.12. Turkey
    • 12.6.12.1. Overview
    • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.12.3. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.12.4. Turkey Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.12.5. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.12.6. Turkey Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.13. Algeria
    • 12.6.13.1. Overview
    • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.13.3. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.13.4. Algeria Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.13.5. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.13.6. Algeria Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.14. Egypt
    • 12.6.14.1. Overview
    • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.14.3. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.14.4. Egypt Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.14.5. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.14.6. Egypt Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.15. Rest of MEA
    • 12.6.15.1. Overview
    • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.15.3. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.15.4. Rest of MEA Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.15.5. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.15.6. Rest of MEA Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Biologics CDMO Industry

• 13.1. Competitive Benchmarking
  • 13.1.1. Competitive Dashboard
  • 13.1.2. Competitive Positioning
• 13.2. Company Profiles
  • 13.2.1. AbbVie Inc.
  • 13.2.2. AGC Biologics
  • 13.2.3. Avid Bioservices
  • 13.2.4. Binex Co. Ltd.
  • 13.2.5. Bioreliance
  • 13.2.6. Bora Pharmaceuticals Co. Ltd.
  • 13.2.7. Catalent
  • 13.2.8. Eurofins Scientific
  • 13.2.9. Evonik Industries AG
  • 13.2.10. Fujifilm Diosynth Biotechnologies
  • 13.2.11. KBI Biopharma
  • 13.2.12. Lonza
  • 13.2.13. Recipharm
  • 13.2.14. Rentschler Biopharma SE
  • 13.2.15. Samsung Biologics
  • 13.2.16. Thermo Fisher Scientific Inc.
  • 13.2.17. WuXi AppTec
  • 13.2.18. 3P Biopharmaceuticals S.L.U.
  • 13.2.19. Others

14. 360 Degree AnalystView

15. Appendix

• 15.1. Research Methodology
• 15.2. References
• 15.3. Abbreviations
• 15.4. Disclaimer
• 15.5. Contact Us